Theravance Biopharma Dirección

Dirección controles de criterios 2/4

El CEO de Theravance Biopharma's es Rick Winningham , nombrado en Jun 2014, tiene una permanencia de 9.83 años. compensación anual total es $4.32M, compuesta por 24.3% salario y 75.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.01% de las acciones de la empresa, por valor de €16.64M. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 7.3 años, respectivamente.

Información clave

Rick Winningham

Chief Executive Officer (CEO)

US$4.3m

Compensación total

Porcentaje del salario del CEO	24.3%
Permanencia del CEO	9.9yrs
Participación del CEO	4.0%
Permanencia media de la dirección	1.9yrs
Promedio de permanencia en la Junta Directiva	7.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rick Winningham en comparación con los beneficios de Theravance Biopharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$4m	US$1m	-US$55m
Sep 30 2023	n/a	n/a	-US$61m
Jun 30 2023	n/a	n/a	-US$68m
Mar 31 2023	n/a	n/a	-US$75m
Dec 31 2022	US$6m	US$1m	-US$93m
Sep 30 2022	n/a	n/a	-US$136m
Jun 30 2022	n/a	n/a	-US$196m
Mar 31 2022	n/a	n/a	-US$226m
Dec 31 2021	US$4m	US$1m	-US$265m
Sep 30 2021	n/a	n/a	-US$266m
Jun 30 2021	n/a	n/a	-US$264m
Mar 31 2021	n/a	n/a	-US$275m
Dec 31 2020	US$7m	US$1m	-US$295m
Sep 30 2020	n/a	n/a	-US$285m
Jun 30 2020	n/a	n/a	-US$270m
Mar 31 2020	n/a	n/a	-US$247m
Dec 31 2019	US$6m	US$984k	-US$236m
Sep 30 2019	n/a	n/a	-US$221m
Jun 30 2019	n/a	n/a	-US$222m
Mar 31 2019	n/a	n/a	-US$223m
Dec 31 2018	US$3m	US$957k	-US$216m
Sep 30 2018	n/a	n/a	-US$252m
Jun 30 2018	n/a	n/a	-US$260m
Mar 31 2018	n/a	n/a	-US$285m
Dec 31 2017	US$2m	US$933k	-US$285m

Compensación vs. Mercado: La compensación total de Rick($USD4.32M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.02M).

Compensación vs. Ingresos: La compensación de Rick ha sido consistente con los resultados de la empresa en el último año.

CEO

Rick Winningham (63 yo)

9.9yrs

Permanencia

US$4,318,531

Compensación

Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022 . He has been Lead Independent Director and Director of Jazz Pharmaceuticals Public Limited Compa...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Rick Winningham	Chairman & CEO	9.9yrs	US$4.32m	4.01% $ 17.1m
Aziz Sawaf	Senior VP & CFO	1.3yrs	US$1.39m	0.49% $ 2.1m
Stuart Knight	VP of IT&I and Chief Information Officer	no data	sin datos	sin datos
Gail Cohen	Vice President of Corporate Communications & Investor Relations	no data	sin datos	sin datos
Brett Grimaud	Senior VP	1.9yrs	sin datos	0.74% $ 3.2m
Rhonda Farnum	Chief Business Officer and Senior VP of Commercial & Medical Affairs	2.4yrs	US$942.81k	0.72% $ 3.1m
Stacy Pryce	Senior VP & Chief Strategy Officer	1.7yrs	sin datos	sin datos
Aine Miller	SVP of Dev.	no data	sin datos	0.35% $ 1.5m

1.9yrs

Permanencia media

53.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0TB no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rick Winningham	Chairman & CEO	10.8yrs	US$4.32m	4.01% $ 17.1m
Eran Broshy	Independent Director	9.9yrs	US$205.14k	0.13% $ 534.8k
Burton Malkiel	Independent Director	10.6yrs	US$206.68k	0.22% $ 935.2k
Deepika Pakianathan	Independent Director	3.8yrs	US$207.68k	0.057% $ 243.7k
Dean Mitchell	Lead Independent Director	9.9yrs	US$211.73k	0.13% $ 534.8k
James Kelly	Independent Director	1.1yrs	US$43.10k	sin datos
Donal O'Connor	Independent Director	8.6yrs	US$195.80k	0.090% $ 385.5k
Susannah Gray	Independent Director	1.3yrs	US$346.47k	0.014% $ 59.3k
Laurie Smaldone Alsup	Independent Director	6.3yrs	US$197.68k	0.092% $ 392.3k
Jeremy Grant	Independent Director	less than a year	US$168.36k	0% $ 0

7.4yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 0TB se considera experimentada (7.3 años de antigüedad promedio).

Theravance Biopharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director

Theravance Biopharma, Inc. Announces Board Changes

Theravance Biopharma, Inc., Annual General Meeting, May 08, 2024

Chairman & CEO recently sold €525k worth of stock

Theravance Biopharma, Inc. Announces Chief Financial Officer Changes

Insufficient new directors

Recent updates

Theravance Biopharma, Inc. to Report Q1, 2024 Results on May 13, 2024

Forecast to breakeven in 2026

Full year 2023 earnings released: US$1.00 loss per share (vs US$1.26 loss in FY 2022)

Theravance Biopharma, Inc. to Report Q4, 2023 Results on Feb 26, 2024

New major risk - Financial position

Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Forecast to breakeven in 2026

Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director

Theravance Biopharma, Inc. Announces Board Changes

Theravance Biopharma, Inc., Annual General Meeting, May 08, 2024

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 3Q 2022)

Theravance Biopharma, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.11 loss in 2Q 2022)

Theravance Biopharma, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Forecast to breakeven in 2024

Full year 2022 earnings released: US$1.26 loss per share (vs US$2.87 loss in FY 2021)

No longer forecast to breakeven

Chairman & CEO recently sold €525k worth of stock

Theravance Biopharma, Inc. Announces Chief Financial Officer Changes

Insufficient new directors

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.48 loss in 3Q 2021)

Theravance Biopharma, Inc. Presents New Ampreloxetine Data in Neurogenic Orthostatic Hypotension

Theravance Biopharma, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $60 million worth of its shares.

Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $250 million worth of its shares.

Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $250 million worth of its shares.

Insider recently sold €130k worth of stock

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.80 loss in 2Q 2021)

Theravance Biopharma, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 85% stake in Theravance Respiratory Company, LLC.

Forecast breakeven date pushed back to 2023

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

First quarter 2022 earnings released: US$0.34 loss per share (vs US$1.24 loss in 1Q 2021)

Theravance Biopharma, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Theravance Biopharma, Inc. Announces Results from Study 0170

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Theravance Biopharma, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study

Senior Vice President of Technical Operations Vijay Sabesan has left the company

Third quarter 2021 earnings released: US$0.48 loss per share (vs US$1.16 loss in 3Q 2020)

Forecast to breakeven in 2023

Independent Director Robert Gunderson has left the company

Independent Director George Whitesides has left the company

Theravance Biopharma, Inc. Announces Top-Line Results from Phase 2B Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

Second quarter 2021 earnings released: US$0.80 loss per share (vs US$1.00 loss in 2Q 2020)

Theravance Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $100.5 million.

Theravance Biopharma, Inc. Announces Top-Line Results from Its Phase 2 Study of 3 Mg Once-Daily Nezulcitinib

First quarter 2021 earnings released: US$1.24 loss per share (vs US$1.40 loss in 1Q 2020)

Senior VP & Chief Medical Officer has left the company

Theravance Biopharma, Inc. Announces Resignation of Brett Haumann as Senior Vice President and Chief Medical Officer Effective April 5, 2021

Insider recently sold €149k worth of stock

Full year 2020 earnings released: US$4.46 loss per share (vs US$4.25 loss in FY 2019)

Revenue misses expectations

Theravance Biopharma, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €16.20

Insider recently sold €120k worth of stock

Insider recently sold €63k worth of stock

Third quarter 2020 earnings released: US$1.16 loss per share

Revenue beats expectations

Theravance Biopharma, Inc., Annual General Meeting, Apr 27, 2021

New 90-day low: €13.70

Senior VP & Chief Medical Officer recently sold €388.2k worth of stock

New 90-day low - €13.80